Received Dec 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 4AB32 | SC |
Shingrix vaccine series administered subcutaneous instead of the intramuscular route; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of intramuscular formulation administered by other route in a 79-year-old female patient who received Herpes zoster (Shingrix) (batch number 4AB32, expiry date 27-MAR-2027) for prophylaxis. On 30-NOV-2025, the patient received the 1st dose of Shingrix (subcutaneous). On 30-NOV-2025, an unknown time after receiving Shingrix, the patient experienced intramuscular formulation administered by other route (Verbatim: Shingrix vaccine series administered subcutaneous instead of the intramuscular route). The outcome of the intramuscular formulation administered by other route was not applicable. Additional Information: GSK Receipt Date: 05-DEC-2025 A pharmacist called to seek guidance after a patient received the first dose of the Shingrix vaccine series administered subcutaneously instead of intramuscularly. The pharmacist wanted to know if the dose was valid or if revaccination was required. SRL 0633 was discussed, and the healthcare professional was satisfied.